<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="en">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">JOP</journal-id>
<journal-id journal-id-type="hwp">spjop</journal-id>
<journal-id journal-id-type="nlm-ta">J Psychopharmacol</journal-id>
<journal-title>Journal of Psychopharmacology</journal-title>
<issn pub-type="ppub">0269-8811</issn>
<issn pub-type="epub">1461-7285</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0269881113492027</article-id>
<article-id pub-id-type="publisher-id">10.1177_0269881113492027</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Reviews</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>A review of the adverse effects and safety of noradrenergic antidepressants</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Whiskey</surname><given-names>Eromona</given-names></name>
<xref ref-type="aff" rid="aff1-0269881113492027">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Taylor</surname><given-names>David</given-names></name>
<xref ref-type="aff" rid="aff1-0269881113492027">1</xref>
<xref ref-type="aff" rid="aff2-0269881113492027">2</xref>
</contrib>
</contrib-group>
<aff id="aff1-0269881113492027"><label>1</label>Pharmacy Department, South London and Maudsley NHS Foundation Trust, London, UK</aff>
<aff id="aff2-0269881113492027"><label>2</label>Institute of Pharmaceutical Science, King’s College London, London, UK</aff>
<author-notes>
<corresp id="corresp1-0269881113492027">David Taylor, South London and Maudsley NHS Foundation Trust, Pharmacy Department, Denmark Hill, London SE5 8AZ, UK. Email: <email>David.Taylor@slam.nhs.uk</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>8</month>
<year>2013</year>
</pub-date>
<volume>27</volume>
<issue>8</issue>
<issue-title>Special issue on Noradrenaline</issue-title>
<fpage>732</fpage>
<lpage>739</lpage>
<permissions>
<copyright-statement>© The Author(s) 2013</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">British Association for Psychopharmacology</copyright-holder>
</permissions>
<abstract>
<p>There are a variety of noradrenergic antidepressants available, most of which act by inhibiting neuronal noradrenaline re-uptake, although few drugs are specific for this action. Where drugs have numerous actions the adverse effects of noradrenaline reuptake may be difficult to isolate, although in this respect the adverse effects of reboxetine, a specific noradrenaline re-uptake inhibitor, are illuminating. Noradrenergic antidepressants typically cause minor changes in blood and heart rate, sweating and insomnia. Other pharmacological actions shown by non-specific antidepressants may act to worsen or mitigate these adverse effects. Noradrenergic drugs are less likely than selective serotonin reuptake inhibitors (SSRIs) to cause sexual dysfunction but more likely to cause urinary hesitancy. Doubts remain over the relative propensity for antidepressants with different modes of action to cause diabetes and hyponatraemia. Noradrenergic actions do not seem to confer a risk of death in overdose.</p>
</abstract>
<kwd-group>
<kwd>Antidepressant agent</kwd>
<kwd>noradrenaline</kwd>
<kwd>adverse drug reaction</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<p>The therapeutic benefits and adverse affects of antidepressants are dependent on several patient and drug variables: dose and drug plasma levels are important factors. Ultimately, effectiveness of psychotherapeutic agents is a consequence of their actions at various receptor sites. Antidepressants differ in their affinity and specificity for serotonin, noradrenaline, dopamine, cholinergic and histamine receptors. This difference is probably reflected more in the tolerability and adverse effects profile of these agents, than in the overall efficacy of the various antidepressant classes.</p>
<p>The role of noradrenaline in the neurobiology of depressive illness is not in doubt, although at present, reboxetine is the only licensed specific noradrenaline reuptake inhibitor (NARI) used in depression. Current evidence suggests that reboxetine is an effective treatment in depression (<xref ref-type="bibr" rid="bibr52-0269881113492027">Medicines and Healthcare Products Regulatory Agency, 2011</xref>), but doubts remain on its role. Concerns have been raised not only about its efficacy, but also about its tolerability and adverse effects (<xref ref-type="bibr" rid="bibr15-0269881113492027">Cipriani et al., 2009</xref>; <xref ref-type="bibr" rid="bibr27-0269881113492027">Eyding et al., 2010</xref>). Viloxazine, a bicylic antidepressant agent with structural similarity to reboxetine, was previously available but has limited clinical utility because of its unusually short half life (<xref ref-type="bibr" rid="bibr68-0269881113492027">Pinder et al., 1977</xref>). Another noradrenaline reuptake inhibitor, atomoxetine is licensed in the treatment of attention deficit hyperactivity disorder (ADHD), but not for depression.</p>
<p>Other classes of antidepressants also have significant effect on the noradrenergic reuptake mechanism, but are not specific to it. Among the tricyclic antidepressants (TCAs), desipramine, lofepramine, amoxapine, doxepin and nortriptyline, are relatively more selective for noradrenaline than serotonin reuptake but are not specific for it (<xref ref-type="bibr" rid="bibr92-0269881113492027">Tatsumi et al., 1997</xref>). The tetracyclic agents, maprotiline and mianserin, are similarly more potent at the noradrenaline transporter than at the serotonin transporter (<xref ref-type="bibr" rid="bibr92-0269881113492027">Tatsumi et al., 1997</xref>). The class of serotonin and noradrenaline reuptake inhibitors (SNRIs) comprise of venlafaxine, duloxetine and milnacipran. As their name implies, they block the reuptake of both noradrenaline and serotonin, although with differing selectivity. Venlafaxine at low doses inhibits serotonin reuptake and at higher doses (150 mg daily or greater), it inhibits reuptake of both serotonin and noradrenaline (<xref ref-type="bibr" rid="bibr62-0269881113492027">Nutt, 2006</xref>). Whereas milnacipan blocks 5-hydroxytryptamine (5-HT) and noradrenaline reuptake with equal affinity, duloxetine has a 10-fold selectivity for 5-HT and venlafaxine has a 30-fold selectivity for 5-HT (<xref ref-type="bibr" rid="bibr85-0269881113492027">Stahl et al., 2005</xref>). It is the net effect of these agents on various receptor sites which ultimately determines their profile of adverse effects.</p>
<p>Here, we focus on the adverse effects associated with noradrenergic reuptake inhibition by antidepressants but include in addition mirtazapine, a drug which enhances noradrenergic action by other means.</p>
<p>We conducted a Medline and EMBASE search using the search terms 'antidepressant', 'noradrenaline', 'norepinephrine', 'noradrenaline reuptake inhibition' and 'adverse effects'. Reference sections of relevant papers were hand searched to retrieve additional references. <xref ref-type="table" rid="table1-0269881113492027">Table 1</xref> below indicates the antidepressants included in this review.</p>
<table-wrap id="table1-0269881113492027" position="float">
<label>Table 1.</label>
<caption>
<p>Antidepressants included in the study.</p>
</caption>
<graphic alternate-form-of="table1-0269881113492027" xlink:href="10.1177_0269881113492027-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th align="left">Antidepressant class</th>
<th align="left">Antidepressants included</th>
</tr>
</thead>
<tbody>
<tr>
<td>Noradrenaline reuptake inhibitors</td>
<td>Reboxetine, atomoxetinea</td>
</tr>
<tr>
<td>Tricyclics</td>
<td>Desipramine, lofepramine, nortriptyline</td>
</tr>
<tr>
<td>Tetracyclics</td>
<td>Maprotiline, mianserin</td>
</tr>
<tr>
<td>Serotonin and noradrenaline reuptake inhibitors</td>
<td>Venlafaxine, duloxetine, milnacipran</td>
</tr>
<tr>
<td>Noradrenergic and specific serotonergic antidepressant</td>
<td>Mirtazapine</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0269881113492027">
<label>a</label>
<p>Licensed for the treatment of attention-deficit/hyperactivity disorder (ADHD).</p>
</fn>
</table-wrap-foot>
</table-wrap>
<sec id="section1-0269881113492027">
<title>Cardiovascular and metabolic side effects of noradrenergic antidepressants</title>
<p>There is a clear link between depression and cardiovascular disease. Prevalence of depression in patients with cardiac disease is higher than the general population and ranges from 16–23% of patients (<xref ref-type="bibr" rid="bibr60-0269881113492027">Musselman et al., 1998</xref>). Depression is about three times more common in patients after an acute myocardial infarction than in the general population (<xref ref-type="bibr" rid="bibr100-0269881113492027">Thombs et al., 2006</xref>) and affects about one in five patients with heart failure (<xref ref-type="bibr" rid="bibr77-0269881113492027">Rutledge et al., 2006</xref>). Similarly, both depression and diabetes are very common medical conditions and frequently co-occur. Various studies have demonstrated significant and consistent association of diabetes complications and depressive symptoms (<xref ref-type="bibr" rid="bibr20-0269881113492027">De Groot et al., 2001</xref>). An understanding of the pharmacological effects of antidepressants is therefore of major importance in the treatment of patients at risk of cardiovascular events.</p>
<p>Reboxetine selectively inhibits the reuptake of noradrenaline but shows only minor affinity for α-adrenergic, muscarinic and histaminic receptors (<xref ref-type="bibr" rid="bibr2-0269881113492027">Agelink et al., 2002</xref>). We can thus ascribe its cardiovascular effects solely to its noradrenergic action. As expected it causes an increase in heart rate and small increases in systolic and diastolic blood pressure (<xref ref-type="bibr" rid="bibr90-0269881113492027">Szabadi et al., 1998</xref>). No clinically significant increase in QT interval has been demonstrated with reboxetine (<xref ref-type="bibr" rid="bibr2-0269881113492027">Agelink et al., 2002</xref>; <xref ref-type="bibr" rid="bibr31-0269881113492027">Fleishaker et al., 2001</xref>). TCAs on the other hand not only inhibit the reuptake of noradrenaline and serotonin, but are potent antagonists at α-adrenergic, muscarinic and histaminic receptors. Therapeutic doses of TCAs cause tachycardia, postural hypotension, QTc interval prolongation, decreased myocardial contractility and cardiac arrhythmias (<xref ref-type="bibr" rid="bibr39-0269881113492027">Jefferson, 1975</xref>; <xref ref-type="bibr" rid="bibr75-0269881113492027">Roos, 1983</xref>). Electrocardiogram (ECG) abnormalities seen with TCAs arise as a result of their potent blockade of cardiac sodium channels and variable activity at potassium channels (<xref ref-type="bibr" rid="bibr96-0269881113492027">Thanacoody and Thomas, 2005</xref>). By comparison with reboxetine, we can infer that much of the cardiac toxicity of TCAs is unrelated to noradrenergic action.</p>
<p>Atomoxetine, another selective noradrenaline reuptake inhibitor licensed in the treatment of ADHD, also affects heart rate and blood pressure. Most patients taking atomoxetine experience a modest increase in heart rate (mean&lt;10 bpm) and/or increase in blood pressure (mean &lt;5 mm Hg). However, combined data from controlled and uncontrolled ADHD clinical trials show that up to 12% of patients experience clinically relevant changes in heart rate (20 bpm or greater) and blood pressure (15–20 mm Hg or greater) (<xref ref-type="bibr" rid="bibr26-0269881113492027">Eli Lilly and Company Limited, 2011</xref>). As with reboxetine, atomoxetine is not associated with QT interval prolongation (<xref ref-type="bibr" rid="bibr111-0269881113492027">Wernicke et al., 2003</xref>).</p>
<p>Duloxetine produces a modest increase in blood pressure and heart rate but there is no evidence that it causes sustained increase in blood pressure (<xref ref-type="bibr" rid="bibr99-0269881113492027">Thase et al., 2005</xref>). Evidence suggests that duloxetine does not affect cardiac ion channels or the Human Ether-a-go-go-Related Gene (HERG) channels which might predict QT prolongation (<xref ref-type="bibr" rid="bibr110-0269881113492027">Wernicke et al., 2007</xref>). Duloxetine, even in large doses up to 200 mg twice daily, did not prolong QTcf interval (<xref ref-type="bibr" rid="bibr110-0269881113492027">Wernicke et al., 2007</xref>).</p>
<p>Venlafaxine has little affinity for α-adrenergic, muscarinic and histaminic receptors. Its side effect profile at lower doses is very similar to that of the selective serotonin reuptake inhibitors (SSRIs) but at higher doses it inhibits noradrenaline reuptake. It causes a dose-dependent increase in blood pressure. At doses greater than 300 mg daily, venlafaxine was associated with a statistically significant increase in blood pressure (<xref ref-type="bibr" rid="bibr97-0269881113492027">Thase, 1998</xref>). During clinical trials, venlafaxine was associated with a mean increase in pulse rate of approximately 3 bpm (<xref ref-type="bibr" rid="bibr76-0269881113492027">Rudolph and Derivan, 1996</xref>). With standard doses, venlafaxine causes no ECG changes and even with high doses does not have any clinical or statistically significant effects on ECG parameters including PR, QT, QRS duration and QTc interval (<xref ref-type="bibr" rid="bibr47-0269881113492027">Mbaya et al., 2007</xref>; <xref ref-type="bibr" rid="bibr93-0269881113492027">Taylor, 2008</xref>; <xref ref-type="bibr" rid="bibr94-0269881113492027">Taylor and Scott, 2006</xref>).</p>
<p>Mirtazapine has a unique pharmacology. It is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine does not inhibit noradrenaline reuptake, the noradrenergic effect is attributed to the blockade of inhibitory presynaptic α<sub>2</sub>-autoreceptors (<xref ref-type="bibr" rid="bibr5-0269881113492027">Anttila and Leinonen, 2001</xref>). In therapeutic doses, mirtazapine is associated with few cardiovascular adverse effects. It is not associated with clinically significant ECG abnormalities. It has a moderate peripheral post-synaptic α<sub>1</sub>-adrenoceptor blocking activity, which can result in a 7% incidence of orthostatic hypotension (<xref ref-type="bibr" rid="bibr44-0269881113492027">Khawaja and Feinstein, 2003</xref>).</p>
</sec>
<sec id="section2-0269881113492027">
<title>Effect of noradrenergic antidepressants on glucose metabolism</title>
<p>Antidepressants can affect appetite, weight and glucose homeostasis. As serotonin, dopamine and noradrenaline regulate a wide variety of feeding behaviours, the changes caused by antidepressants are likely to be related to their affinity for these neurotransmitters (<xref ref-type="bibr" rid="bibr49-0269881113492027">McIntyre et al., 2006</xref>). Data on the risk of diabetes associated with the use antidepressants are limited (<xref ref-type="bibr" rid="bibr4-0269881113492027">Andersohn et al., 2009</xref>). There is some evidence that the risk of diabetes with serotonergic antidepressants may be lower than that with TCA (<xref ref-type="bibr" rid="bibr12-0269881113492027">Brown et al., 2008</xref>). It would seem that overall, noradrenergic antidepressants may have a very small but negative effect on glucose homeostasis whereas serotonergic antidepressants tend to have a more favourable profile (<xref ref-type="bibr" rid="bibr24-0269881113492027">Deuschle, 2013</xref>)</p>
</sec>
<sec id="section3-0269881113492027">
<title>Sexual side effects of noradrenergic antidepressants</title>
<p>The relationship between depression, antidepressant treatment and sexual function is a complex one. Sexual dysfunction is highly prevalent in depressive illness. It has been estimated that 40% of men and 50% of women with major depression report a decrease in libido with fewer reports of difficulties with erection/ejaculation (22% of men) or orgasm (15% of women) prior to taking antidepressant treatment (<xref ref-type="bibr" rid="bibr43-0269881113492027">Kennedy et al., 1999</xref>). In some patients, treatment of the depressive episode results in resolution of the sexual dysfunction. However, treatment-emergent sexual dysfunction has been associated with virtually all antidepressants to varying degrees, and available data suggest that the variation can be attributed, at least in part, to the mechanism of action of the antidepressant (<xref ref-type="bibr" rid="bibr16-0269881113492027">Clayton and Montejo, 2006</xref>).</p>
<p>While dopamine is known to enhance sexual function, serotonin stimulation inhibits sexual desire, ejaculation and orgasm but the precise role of noradrenaline is unclear (<xref ref-type="bibr" rid="bibr56-0269881113492027">Montejo et al., 2001</xref>). The incidence of sexual dysfunction is highest with serotonergic antidepressants whilst drugs that predominantly affect noradrenaline or dopamine cause fewer sexual side effects (although a low rate of sexual effects is usually seen) (<xref ref-type="bibr" rid="bibr95-0269881113492027">Taylor et al., 2012</xref>; <xref ref-type="bibr" rid="bibr109-0269881113492027">Werneke et al., 2006</xref>)</p>
<p>The effect of reboxetine on sexual function has been compared with that of SSRIs, citalopram, paroxetine and fluoxetine (<xref ref-type="bibr" rid="bibr6-0269881113492027">Baldwin et al., 2006</xref>; <xref ref-type="bibr" rid="bibr17-0269881113492027">Clayton et al., 2003</xref>; <xref ref-type="bibr" rid="bibr46-0269881113492027">Langworth et al., 2006</xref>). Overall, sexual adverse effects such as anorgasmia, reduced libido etc. were reported much more commonly with the SSRIs. Reboxetine appears comparable to placebo in all aspects of sexual functioning except for male arousal problems (<xref ref-type="bibr" rid="bibr17-0269881113492027">Clayton et al., 2003</xref>). Ejaculatory dysfunction in men has been reported with reboxetine and this is thought to be consistent with its noradrenergic mechanism (<xref ref-type="bibr" rid="bibr35-0269881113492027">Giuliano and Rampin, 2000</xref>; <xref ref-type="bibr" rid="bibr69-0269881113492027">Preskorn, 2004</xref>).</p>
<p>TCAs have the potential to cause sexual dysfunction in all sexual response phases. The potential for sexual dysfunction also appears to correlate to affinity for serotonergic receptors, with prevalence being higher for agents such as clomipramine. For example, there are reports of clomipramine-induced sexual dysfunction being resolved by switching to the noradrenergic TCA, desipramine (<xref ref-type="bibr" rid="bibr70-0269881113492027">Quirk and Einarson, 1982</xref>). The anticholinergic effects of TCAs also contribute to the spectrum of sexual dysfunction of these agents (<xref ref-type="bibr" rid="bibr109-0269881113492027">Werneke et al., 2006</xref>).</p>
<p>There is evidence that SNRIs are associated with high rates of sexual side effects. The rate of sexual adverse effects with venlafaxine appears to be similar to that observed with SSRIs, with incidence ranging from 58–73% (<xref ref-type="bibr" rid="bibr56-0269881113492027">Montejo et al., 2001</xref>). Duloxetine on the other hand appears to be associated with lower rates of sexual dysfunction when compared with SSRIs. In four double blind-blind, paroxetine-controlled trials, duloxetine was associated with significantly lower incidence of treatment-emergent sexual dysfunction than paroxetine, although both drugs had rates that were significantly higher than those for placebo (<xref ref-type="bibr" rid="bibr21-0269881113492027">Delgado et al., 2005</xref>). The lower incidence of sexual side effects with duloxetine relative to SSRIs may possibly be explained because some evidence suggests that noradrenergic effects may mitigate the serotonin influence on sexual function (<xref ref-type="bibr" rid="bibr42-0269881113492027">Kennedy and Rizvi, 2009</xref>). Similarly, at least in theory, the use of higher doses of venlafaxine, where inhibition of noradrenaline and dopamine occurs, should be associated with a reduced risk of sexual side effects (<xref ref-type="bibr" rid="bibr109-0269881113492027">Werneke et al., 2006</xref>).</p>
<p>Mirtazapine is associated with low risk of sexual dysfunction. Detailed mechanisms of mirtazapine on sexual function are unclear but likely to involve blockade of 5-HT<sub>2</sub>. In addition, the α<sub>2</sub>-adrenoceptor blockade property of mirtazapine has been shown to enhance erectile function (<xref ref-type="bibr" rid="bibr59-0269881113492027">Munoz et al., 1994</xref>). Orgasmic dysfunction seems to be linked to the decreased dopamine and noradrenaline levels induced by 5-HT2 receptor activation (<xref ref-type="bibr" rid="bibr80-0269881113492027">Serretti and Chiesa, 2009</xref>) by SSRIs and SNRIs. The addition of, or switching to, mirtazapine from serotonergic antidepressants is an acceptable strategy in managing antidepressant-induced sexual dysfunction (<xref ref-type="bibr" rid="bibr33-0269881113492027">Gelenberg et al., 2000</xref>; <xref ref-type="bibr" rid="bibr63-0269881113492027">Ozmenler et al., 2008</xref>; <xref ref-type="bibr" rid="bibr73-0269881113492027">Ravindran et al., 2008</xref>) .</p>
</sec>
<sec id="section4-0269881113492027">
<title>Autonomic adverse effects of noradrenergic antidepressants</title>
<sec id="section5-0269881113492027">
<title>Genitourinary adverse effects</title>
<p>Various neurotransmitters have been implicated in central control of the lower urinary tract. For example, dopamine, noradrenaline, serotonin, acetylcholine, gamma-aminobutyric acid (GABA), and non-opioid peptides, including vasoactive intestinal polypeptide and corticotropin-releasing factor have either inhibitory or excitatory effects, depending on the type of receptor that is activated (<xref ref-type="bibr" rid="bibr32-0269881113492027">Fowler et al., 2008</xref>).</p>
<p>Noradrenergic stimulation tends to increase bladder outlet resistance, while drugs with α-adrenergic blocking activity tend to decrease bladder outlet resistance. Dysuria, urinary retention, and a sensation of incomplete bladder emptying are commonly occurring side effects of noradrenergic agents. In a randomised, double-blind multicentre study, urinary hesitancy and/or retention occurred in 7.7% of reboxetine-treated patients (<italic>n</italic>=130) as compared to 4.8% of imipramine-treated patients (<italic>n</italic>=126) (<xref ref-type="bibr" rid="bibr10-0269881113492027">Berzewski et al., 1997</xref>). Consistent with its noradrenergic mechanism, there are case reports of the use of α-adrenergic blocking drugs such as doxazocin (<xref ref-type="bibr" rid="bibr89-0269881113492027">Szabadi, 1998</xref>) and tamsulosin (<xref ref-type="bibr" rid="bibr22-0269881113492027">Demyttenaere et al., 2001</xref>; <xref ref-type="bibr" rid="bibr40-0269881113492027">Kasper and Wolf, 2002</xref>) for the treatment of reboxetine-associated urinary hesitancy/retention.</p>
<p>The TCAs interact with multiple receptors affecting the lower urinary tract and, in particular, have potent anticholinergic properties. In a comparison between reboxetine and desipramine using the Newly Observed Signs and Symptoms (NOSS) checklist, reboxetine was associated with significantly greater frequency of reports of urinary hesitancy (12% versus 4%) (<xref ref-type="bibr" rid="bibr103-0269881113492027">Versiani et al, 2000</xref>).</p>
<p>Atomoxetine is also commonly associated with urinary hesitancy and or urinary retention. The tolerability profile of atomoxetine in adults differs somewhat from that seen in children, with more adverse events consistent with increased noradrenergic tone (<xref ref-type="bibr" rid="bibr55-0269881113492027">Michelson et al., 2003</xref>). In adult ADHD controlled trials, the rates of urinary retention (1.7%, 9/540) and urinary hesitation (5.6%, 30/540) were increased among atomoxetine subjects compared with placebo subjects (0%, 0/402; 0.5%, 2/402, respectively) (<xref ref-type="bibr" rid="bibr55-0269881113492027">Michelson et al., 2003</xref>). Atomoxetine has been investigated as a treatment for nocturnal enuresis in children (<xref ref-type="bibr" rid="bibr88-0269881113492027">Sumner et al., 2006</xref>).</p>
<p>Duloxetine is licensed in the treatment of stress urinary incontinence, depression, generalised anxiety disorder and diabetic peripheral neuropathic pain. It has been demonstrated to significantly increase bladder capacity and increase urethral closure (<xref ref-type="bibr" rid="bibr101-0269881113492027">Thor et al., 2007</xref>). Urinary retention and hesitancy are described as uncommon side effects by the manufacturer (<xref ref-type="bibr" rid="bibr25-0269881113492027">Eli Lilly and Company Limited, 2012</xref>). In 1139 patients with major depression treated with duloxetine in placebo-controlled trials, subjective urinary retention was reported in 0.4% (4/1139) patients (<xref ref-type="bibr" rid="bibr105-0269881113492027">Viktrup et al., 2004</xref>).</p>
<p>Venlafaxine has been associated with both urinary retention and urinary incontinence. Although urinary retention appears to be more commonly reported impairment in urinary function (<xref ref-type="bibr" rid="bibr67-0269881113492027">Pfizer Limited, 2012</xref>), a comparison of standard versus high dose venlafaxine demonstrated urinary frequency occurred more frequently at higher doses (5% versus 0%) (<xref ref-type="bibr" rid="bibr98-0269881113492027">Thase et al., 2006</xref>).</p>
</sec>
</sec>
<sec id="section6-0269881113492027">
<title>Sweating</title>
<p>The mechanism of antidepressant-induced sweating is not clear. All classes of antidepressants have been implicated in causing sweating, implying the involvement of various neurotransmitter systems (<xref ref-type="bibr" rid="bibr50-0269881113492027">Marcy and Britton, 2005</xref>). Noradrenaline has the potential to stimulate sweat glands (<xref ref-type="bibr" rid="bibr50-0269881113492027">Marcy and Britton, 2005</xref>). Excessive sweating occurs in about 12% of reboxetine-treated patients (<xref ref-type="bibr" rid="bibr103-0269881113492027">Versiani et al., 2000</xref>). Clonidine, a centrally-acting presynaptic α-agonist has been reportedly used to treat antidepressant-induced sweating (<xref ref-type="bibr" rid="bibr29-0269881113492027">Feder, 1995</xref>). Terazosin, a post synaptic α-blocker has also been similarly used (<xref ref-type="bibr" rid="bibr34-0269881113492027">Ghaleiha et al., 2012</xref>).</p>
<p>Sweating is a frequently occurring side effect of TCA treatment. Systematic reviews and meta-analytic studies show that it is present in 12–15% of treated patients (<xref ref-type="bibr" rid="bibr66-0269881113492027">Peretti et al., 2000</xref>; <xref ref-type="bibr" rid="bibr102-0269881113492027">Trindade et al., 1998</xref>). Despite the multiple interaction of TCAs with various receptors implicated in sweating, there is little difference in the reported rates of sweating between reboxetine and TCAs (<xref ref-type="bibr" rid="bibr10-0269881113492027">Berzewski et al., 1997</xref>).</p>
<p>In trials involving atomoxetine in adult ADHD patients, sweating was one of the adverse effects more frequently reported, occurring in 5.2% of treated patients compared with 0.8% in placebo-treated patients (<xref ref-type="bibr" rid="bibr81-0269881113492027">Simpson and Plosker, 2004</xref>).</p>
<p>The SNRIs, venlafaxine and duloxetine, frequently cause sweating occurring in 5–20% of treated patients (<xref ref-type="bibr" rid="bibr54-0269881113492027">Mehtonen et al., 2000</xref>; <xref ref-type="bibr" rid="bibr72-0269881113492027">Raskin et al., 2003</xref>). The risk is greater with SNRIs than with SSRIs (<xref ref-type="bibr" rid="bibr57-0269881113492027">Montgomery et al., 2004</xref>) and it appears to be a dose-related adverse effect (<xref ref-type="bibr" rid="bibr23-0269881113492027">Detke et al., 2004</xref>; <xref ref-type="bibr" rid="bibr57-0269881113492027">Montgomery et al., 2004</xref>; <xref ref-type="bibr" rid="bibr72-0269881113492027">Raskin et al., 2003</xref>), suggesting a clear role for noradrenaline reuptake inhibition.</p>
<p>Risk of sweating with mirtazapine is low. It is much less likely than the SSRIs or SNRIs to cause sweating (<xref ref-type="bibr" rid="bibr108-0269881113492027">Watanabe et al., 2010</xref>). Indeed, mirtazapine has been used to treat SSRI-induced sweating (<xref ref-type="bibr" rid="bibr13-0269881113492027">Buecking et al., 2005</xref>).</p>
</sec>
<sec id="section7-0269881113492027">
<title>Other autonomic adverse effects</title>
<p>Constipation and dry mouth are some of the most frequently occurring side effects associated with noradrenergic antidepressants. About 18% of reboxetine-treated patients complain of constipation and 14-27% of patients have dry mouth during reboxetine treatment (<xref ref-type="bibr" rid="bibr7-0269881113492027">Ban et al., 1998</xref>; <xref ref-type="bibr" rid="bibr79-0269881113492027">Schatzberg, 2000</xref>; <xref ref-type="bibr" rid="bibr91-0269881113492027">Tanum, 2000</xref>). As expected, these anticholinergic-type side effects occur more frequently with TCAs than with reboxetine. In a trial comparing reboxetine with imipramine in elderly depressed patients, constipation and dry mouth were more frequently reported with imipramine (<xref ref-type="bibr" rid="bibr41-0269881113492027">Katona et al., 1999</xref>). On the other hand, when a selective noradrenergic agent is compared with a mixed reuptake inhibitor such as venlafaxine, such adverse effects occur much more frequently with the pure adrenergic agents (<xref ref-type="bibr" rid="bibr3-0269881113492027">Akkaya et al., 2006</xref>).</p>
<sec id="section8-0269881113492027">
<title>Hyponatraemia</title>
<p>Hyponatraemia, a potentially life-threatening adverse effect has been associated with all classes of antidepressants. The most likely mechanism of this adverse effect is the syndrome of inappropriate secretion of antidiuretic hormone (SIADH) (<xref ref-type="bibr" rid="bibr95-0269881113492027">Taylor et al., 2012</xref>) . It has been suggested that serotonergic antidepressants are more likely than noradrenergic to trigger hyponatraemia although the evidence is inconclusive (<xref ref-type="bibr" rid="bibr18-0269881113492027">Coupland et al., 2011</xref>; <xref ref-type="bibr" rid="bibr58-0269881113492027">Movig et al., 2002</xref>). An important confounder is that SSRIs are used preferentially in elderly depressed patients. Old age and medical co-morbidity are established risk factors for hyponatraemia. Well designed controlled studies to examine the risk of hyponatraemia associated with different types of antidepressants are lacking. A study available only as a conference abstract suggested that there was no statistically significant difference in the development of hyponatraemia between the TCA and SSRI groups (<xref ref-type="bibr" rid="bibr65-0269881113492027">Parmar and Behere, 2010</xref>).</p>
<p>Guidelines suggest that if a patient develops hyponatraemia on an SSRI, a switch to a noradrenergic agent should be considered (<xref ref-type="bibr" rid="bibr95-0269881113492027">Taylor et al., 2012</xref>). Although this is a pragmatic approach, the evidence on which this is based is not robust. Certainly there are case reports of hyponatraemia with reboxetine (<xref ref-type="bibr" rid="bibr1-0269881113492027">Abdelrahman et al., 2003</xref>; <xref ref-type="bibr" rid="bibr71-0269881113492027">Ranieri et al., 2000</xref>), and with noradrenergic tricyclic agents such as lofepramine (<xref ref-type="bibr" rid="bibr11-0269881113492027">Bouman et al., 1997</xref>), desipramine and nortriptyline. A case of atomoxetine-induced hyponatraemia has also been published (<xref ref-type="bibr" rid="bibr82-0269881113492027">Singh, 2007</xref>). Further studies are therefore needed to characterise the risk associated with different classes of antidepressants.</p>
</sec>
</sec>
<sec id="section9-0269881113492027">
<title>Insomnia</title>
<p>Disturbance of sleep is a core symptom of depression. Abnormalities of rapid eye movement (REM) sleep are frequently observed in depressive disorder (<xref ref-type="bibr" rid="bibr9-0269881113492027">Berger and Riemann, 1993</xref>). Treatment with an antidepressant can have beneficial or deleterious effect on sleep. The SSRIs are frequently associated with insomnia because of 5-HT<sub>2</sub> receptor stimulation. Central noradrenergic stimulation is also associated with arousal, activation and insomnia (<xref ref-type="bibr" rid="bibr83-0269881113492027">Southwick et al., 1999</xref>; <xref ref-type="bibr" rid="bibr84-0269881113492027">Stahl, 1998</xref>).</p>
<p>Insomnia is a very commonly reported side effect of reboxetine. In an analysis of nine short-term, double-blind, randomised clinical trials in patients with depression, reboxetine was associated with a significant increase in treatment-emergent insomnia in the first week of treatment (<xref ref-type="bibr" rid="bibr86-0269881113492027">Stahl et al., 2002</xref>). In a study in which 128 patients with depression who had not responded to at least 6–12 weeks of fluoxetine were switched to reboxetine, the most commonly reported treatment-emergent adverse effect was insomnia occurring in 41.4% of treated patients. There was a tendency for this adverse effect to decrease over time (<xref ref-type="bibr" rid="bibr28-0269881113492027">Fava et al., 2003</xref>). Compared with the SSRIs, reboxetine-treated patients were more likely to experience insomnia (<xref ref-type="bibr" rid="bibr64-0269881113492027">Papakostas et al., 2008</xref>). Like most antidepressants, reboxetine causes suppression of REM sleep accompanied by sleep latency (<xref ref-type="bibr" rid="bibr30-0269881113492027">Ferini-Strambi et al., 2004</xref>; <xref ref-type="bibr" rid="bibr45-0269881113492027">Kuenzel et al., 2004</xref>)</p>
<p>The TCAs very rarely cause insomnia. On the contrary, they commonly cause sedation because they are potent histamine H1 receptor antagonists. The degree of sedation with TCAs appears to be related to their potency at the H1 receptors. The most potent antihistamine, doxepin hydrocholoride, was about four times more potent than amitriptyline hydrochloride and about 8000 times more potent than desipramine hydrochloride, the least potent TCA at the histamine H1 receptor (<xref ref-type="bibr" rid="bibr74-0269881113492027">Richelson, 1979</xref>). The frequency of sedation is thus less with desipramine and nortriptyline.</p>
<p>Insomnia is one of the most commonly reported adverse effects with atomoxetine therapy. In placebo-controlled adult ADHD trials, the frequency of insomnia was 20.8% compared with 8.7% placebo treated patients (<xref ref-type="bibr" rid="bibr81-0269881113492027">Simpson and Plosker, 2004</xref>).</p>
<p>The incidence of insomnia with venlafaxine appears to be similar to that with SSRIs (<xref ref-type="bibr" rid="bibr54-0269881113492027">Mehtonen et al., 2000</xref>) whereas duloxetine, which is relatively more adrenergic than venlafaxine, appears to be associated with a higher frequency of insomnia compared with SSRIs (<xref ref-type="bibr" rid="bibr107-0269881113492027">Wade et al., 2007</xref>).</p>
<p>Mirtazapine has potent antihistaminic effects and somnolence is one the commonest side effects associated with its use. Lower doses of mirtazapine have been reported to be more sedating than higher doses. This reverse dose-response effect has been ascribed to the central noradrenergic effect which partially offsets the sedation from histamine blockade (<xref ref-type="bibr" rid="bibr19-0269881113492027">De Boer, 1996</xref>). Mirtazapine increases sleep efficiency and sleep latency, an effect that is consistent with its stimulatory effects on post synaptic 5-HT and noradrenaline receptors (<xref ref-type="bibr" rid="bibr61-0269881113492027">Nutt, 2002</xref>).</p>
</sec>
<sec id="section10-0269881113492027">
<title>Safety in overdose</title>
<p>Only a handful of cases of reboxetine overdose have been published in the literature. No fatalities have been reported following overdoses. The largest amount ingested in overdose published is 240 mg of reboxetine which is 20 times the maximum recommended dose (<xref ref-type="bibr" rid="bibr14-0269881113492027">Burns, 2000</xref>). Clinical effects in overdose are expected from noradrenergic reuptake inhibition: sweating, tachycardia, anxiety, agitation and hypertension.</p>
<p>Concern has been raised about the possible risk of increased risk of suicidal thoughts or behaviour in association with the use of atomoxetine. In a meta-analysis of fourteen trials, the frequency of suicidal ideation was 0.37% (5/1357) in paediatric patients taking atomoxetine versus 0% (0/851) for the placebo group (<xref ref-type="bibr" rid="bibr8-0269881113492027">Bangs et al., 2008</xref>). A Europe-wide review concluded that the overall balance of risks and benefits of atomoxetine remains positive in the treatment of ADHD in children of six years and older and in adolescents (<xref ref-type="bibr" rid="bibr53-0269881113492027">MHRA, 2006</xref>).</p>
<p>Data on overdose with atomoxetine are also limited. Drowsiness, mild tachycardia and hypertension, nausea and vomiting, nystagmus, tremor, and rarely seizures have been reported after overdose. A 15-year old boy intentionally took an overdose of 1200 mg of atomoxetine. Within three hours, he had developed a generalised seizure and his QTc was 607 msec at three hours and 435 msec at six hours after ingestion. He was discharged two days later (<xref ref-type="bibr" rid="bibr78-0269881113492027">Sawant and Daviss, 2004</xref>).</p>
<p>TCAs are especially toxic and cardiovascular toxicity is the leading cause of death in overdose. The relatively greater toxicity of TCAs can be attributable to the potent blockade of ion channels and thus increasing heart rate and prolonging QTc. The propensity for serious toxicity even differs among the TCAs with dosulepin and doxepine being more toxic (<xref ref-type="bibr" rid="bibr36-0269881113492027">Hawton et al., 2010</xref>), whereas lofepramine is less toxic in overdose (<xref ref-type="bibr" rid="bibr37-0269881113492027">Henry et al., 1995</xref>).</p>
<p>The features of venlafaxine toxicity result from serotonergic and noradrenergic over-stimulation. This includes dizziness, fatigue, tremor, agitation, coma and convulsions. Nausea and vomiting, dilated pupils and sweating may occur. Life-threatening cardiovascular toxicity manifested by ventricular dysrhythmias are associated with massive overdoses. Although some reports have suggested greater cardiovascular toxicity of venlafaxine in overdose, a large population based study showed that the use of venlafaxine was not associated with an excess risk of sudden cardiac death or near death compared with fluoxetine, dosulepin or citalopram (<xref ref-type="bibr" rid="bibr51-0269881113492027">Martinez et al., 2010</xref>).</p>
<p>Data on duloxetine toxicity are limited. According to the manufacturer, cases of overdoses, alone or in combination with other medicinal products, with duloxetine doses of 5400 mg have been reported and some fatalities have been recorded primarily with mixed overdoses. The largest single overdose of duloxetine resulting in fatality is approximately 1000 mg (<xref ref-type="bibr" rid="bibr25-0269881113492027">Eli Lilly and Company Limited, 2012</xref>) Vomiting, tachycardia, drowsiness, coma, seizures and serotonin syndrome, have been reported after overdose. Prolongation of the QT and QRS duration and ventricular arrhythmias can also occur but the risk appears to be low (<xref ref-type="bibr" rid="bibr38-0269881113492027">Jacob et al., 2012</xref>) .</p>
<p>There were initial concerns regarding hepatotoxicity with duloxetine although the risk posed does not appear to be greater when compared to other conventional antidepressants (<xref ref-type="bibr" rid="bibr48-0269881113492027">McIntyre et al., 2008</xref>; <xref ref-type="bibr" rid="bibr87-0269881113492027">Strombom et al., 2008</xref>). It is contraindicated in liver disease resulting in hepatic impairment. Cases of liver injury, including severe elevations of liver enzymes (&gt;10times upper limit of normal), hepatitis, and jaundice have been reported with duloxetine (<xref ref-type="bibr" rid="bibr25-0269881113492027">Eli Lilly and Company Limited, 2012</xref>). Onset is usually within two months of initiation and the risk appears to be higher in patients with a history of alcohol misuse and those with a pre-existing chronic liver disease (<xref ref-type="bibr" rid="bibr106-0269881113492027">Vuppalanchi et al., 2010</xref>) . Risk of liver abnormalities also appear to be dose related (<xref ref-type="bibr" rid="bibr104-0269881113492027">Vey and Kovelman, 2010</xref>). It would be prudent therefore to assess baseline liver function before starting treatment.</p>
</sec>
<sec id="section11-0269881113492027" sec-type="conclusions">
<title>Conclusion</title>
<p>Noradrenergic antidepressants cause a range of predictable adverse effects which have the potential to lead to treatment discontinuation. Cardiac effects are usually limited to small rises in blood pressure and pulse rate although clinically important changes sometimes occur. Prolongation of the QT interval is not linked to the noradrenergic effect of antidepressants and many noradrenergic drugs have no important effect on QT. Sexual adverse effects are limited to male arousal difficulties and are much less common than with serotonergic drugs. Noradrenergic effects may also occasionally cause urinary hesitancy or retention and more frequently constipation and dry mouth. Sweating and insomnia are fairly common adverse effects of noradrenergic agents and either can be considered intolerable by patients. Noradrenergic antidepressants are generally safe in overdose.</p>
<p>Despite the range of adverse effects associated with noradrenergic antidepressants, they are probably no less well tolerated than serotonergic antidepressants. Indeed they present a useful alternative to serotonergic drugs where, for example, sexual dysfunction is intolerable or where serotonergic drugs are contra-indicated because of their effects on clotting or cardiac conduction.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="financial-disclosure">
<label>Funding</label>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors</p>
</fn>
<fn fn-type="conflict">
<label>Conflict of interest</label>
<p>The authors declare that there are no conflicts of interest.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Abdelrahman</surname><given-names>N</given-names></name>
<name><surname>Kleinman</surname><given-names>Y</given-names></name>
<name><surname>Rund</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Hyponatremia associated with the initiation of reboxetine therapy</article-title>. <source>Eur J Clin Pharmacol</source> <volume>59</volume>: <fpage>177</fpage>.</citation>
</ref>
<ref id="bibr2-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Agelink</surname><given-names>MW</given-names></name>
<name><surname>Ullrich</surname><given-names>H</given-names></name>
<name><surname>Baumann</surname><given-names>B</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Effects of reboxetine, a selective norepinephrine reuptake inhibitor, on sympathetic and parasympathetic outflow to the heart: Preliminary data</article-title>. <source>Psychopharmacology (Berl)</source> <volume>163</volume>: <fpage>151</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr3-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Akkaya</surname><given-names>C</given-names></name>
<name><surname>Sivrioglu</surname><given-names>EY</given-names></name>
<name><surname>Akgoz</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Comparison of efficacy and tolerability of reboxetine and venlafaxine XR in major depression and major depression with anxiety features: An open label study</article-title>. <source>Hum Psychopharmacol</source> <volume>21</volume>: <fpage>337</fpage>–<lpage>345</lpage>.</citation>
</ref>
<ref id="bibr4-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Andersohn</surname><given-names>F</given-names></name>
<name><surname>Schade</surname><given-names>R</given-names></name>
<name><surname>Suissa</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Long-term use of antidepressants for depressive disorders and the risk of diabetes mellitus</article-title>. <source>Am J Psychiatry</source> <volume>166</volume>: <fpage>591</fpage>–<lpage>598</lpage>.</citation>
</ref>
<ref id="bibr5-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Anttila</surname><given-names>SA</given-names></name>
<name><surname>Leinonen</surname><given-names>EV</given-names></name>
</person-group> (<year>2001</year>) <article-title>A review of the pharmacological and clinical profile of mirtazapine</article-title>. <source>CNS Drug Rev</source> <volume>7</volume>: <fpage>249</fpage>–<lpage>264</lpage>.</citation>
</ref>
<ref id="bibr6-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Baldwin</surname><given-names>D</given-names></name>
<name><surname>Bridgman</surname><given-names>K</given-names></name>
<name><surname>Buis</surname><given-names>C</given-names></name>
</person-group> (<year>2006</year>) <article-title>Resolution of sexual dysfunction during double-blind treatment of major depression with reboxetine or paroxetine</article-title>. <source>J Psychopharmacol</source> <volume>20</volume>: <fpage>91</fpage>–<lpage>96</lpage>.</citation>
</ref>
<ref id="bibr7-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ban</surname><given-names>TA</given-names></name>
<name><surname>Gaszner</surname><given-names>P</given-names></name>
<name><surname>Aguglia</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Clinical efficacy of reboxetine: A comparative study with desipramine, with methodological considerations</article-title>. <source>Hum Psychopharmacol</source> <volume>13</volume>: <fpage>S29</fpage>-<lpage>S39</lpage>.</citation>
</ref>
<ref id="bibr8-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bangs</surname><given-names>ME</given-names></name>
<name><surname>Tauscher-Wisniewski</surname><given-names>S</given-names></name>
<name><surname>Polzer</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Meta-analysis of suicide-related behavior events in patients treated with atomoxetine</article-title>. <source>J Am Acad Child Adolesc Psychiatry</source> <volume>47</volume>: <fpage>209</fpage>–<lpage>218</lpage>.</citation>
</ref>
<ref id="bibr9-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berger</surname><given-names>M</given-names></name>
<name><surname>Riemann</surname><given-names>D</given-names></name>
</person-group> (<year>1993</year>) <article-title>Symposium: Normal and abnormal REM sleep regulation: REM sleep in depression-an overview</article-title>. <source>J Sleep Res</source> <volume>2</volume>: <fpage>211</fpage>–<lpage>223</lpage>.</citation>
</ref>
<ref id="bibr10-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Berzewski</surname><given-names>H</given-names></name>
<name><surname>Van</surname><given-names>MM</given-names></name>
<name><surname>Gagiano</surname><given-names>CA</given-names></name>
</person-group> (<year>1997</year>) <article-title>Efficacy and tolerability of reboxetine compared with imipramine in a double-blind study in patients suffering from major depressive offsodes</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>7</volume>: <fpage>S37</fpage>-<lpage>S47</lpage>.</citation>
</ref>
<ref id="bibr11-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bouman</surname><given-names>WP</given-names></name>
<name><surname>Johnson</surname><given-names>H</given-names></name>
<name><surname>Trescoli-Serrano</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Recurrent hyponatremia associated with sertraline and lofepramine</article-title>. <source>Am J Psychiatry</source> <volume>154</volume>: <fpage>580</fpage>.</citation>
</ref>
<ref id="bibr12-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Brown</surname><given-names>LC</given-names></name>
<name><surname>Majumdar</surname><given-names>SR</given-names></name>
<name><surname>Johnson</surname><given-names>JA</given-names></name>
</person-group> (<year>2008</year>) <article-title>Type of antidepressant therapy and risk of type 2 diabetes in people with depression</article-title>. <source>Diabetes Res Clin Pract</source> <volume>79</volume>: <fpage>61</fpage>–<lpage>67</lpage>.</citation>
</ref>
<ref id="bibr13-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Buecking</surname><given-names>A</given-names></name>
<name><surname>Vandeleur</surname><given-names>CL</given-names></name>
<name><surname>Khazaal</surname><given-names>Y</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Mirtazapine in drug-induced excessive sweating</article-title>. <source>Eur J Clin Pharmacol</source> <volume>61</volume>: <fpage>543</fpage>–<lpage>544</lpage>.</citation>
</ref>
<ref id="bibr14-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Burns</surname><given-names>MJ</given-names></name>
</person-group> (<year>2000</year>) <article-title>The pharmacology and toxicology of reboxetine</article-title>. <source>Int J Med Toxicol</source> <volume>3</volume>: <fpage>1</fpage>–<lpage>7</lpage>.</citation>
</ref>
<ref id="bibr15-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Cipriani</surname><given-names>A</given-names></name>
<name><surname>Furukawa</surname><given-names>TA</given-names></name>
<name><surname>Salanti</surname><given-names>G</given-names></name><etal/>
</person-group>. (<year>2009</year>) <article-title>Comparative efficacy and acceptability of 12 new-generation antidepressants: A multiple-treatments meta-analysis</article-title>. <source>Lancet</source> <volume>373</volume>: <fpage>746</fpage>–<lpage>758</lpage>.</citation>
</ref>
<ref id="bibr16-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clayton</surname><given-names>AH</given-names></name>
<name><surname>Montejo</surname><given-names>AL</given-names></name>
</person-group> (<year>2006</year>) <article-title>Major depressive disorder, antidepressants, and sexual dysfunction</article-title>. <source>J Clin Psychiatry</source> <volume>67</volume>: <fpage>S33</fpage>–<lpage>S37</lpage>.</citation>
</ref>
<ref id="bibr17-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Clayton</surname><given-names>AH</given-names></name>
<name><surname>Zajecka</surname><given-names>J</given-names></name>
<name><surname>Ferguson</surname><given-names>JM</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder</article-title>. <source>Int Clin Psychopharmacol</source> <volume>18</volume>: <fpage>151</fpage>–<lpage>156</lpage>.</citation>
</ref>
<ref id="bibr18-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Coupland</surname><given-names>C</given-names></name>
<name><surname>Dhiman</surname><given-names>P</given-names></name>
<name><surname>Morriss</surname><given-names>R</given-names></name><etal/>
</person-group>. (<year>2011</year>) <article-title>Antidepressant use and risk of adverse outcomes in older people: Population based cohort study</article-title>. <source>Brit Med J</source> <volume>343</volume>: <fpage>d4551</fpage>.</citation>
</ref>
<ref id="bibr19-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Boer</surname><given-names>T</given-names></name>
</person-group> (<year>1996</year>) <article-title>The pharmacologic profile of mirtazapine</article-title>. <source>J Clin Psychiatry</source> <volume>57</volume>: <fpage>S19</fpage>–<lpage>S25</lpage>.</citation>
</ref>
<ref id="bibr20-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>De Groot</surname><given-names>M.</given-names></name>
<name><surname>Anderson</surname><given-names>R</given-names></name>
<name><surname>Freedland</surname><given-names>KE</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Association of depression and diabetes complications: A meta-analysis</article-title>. <source>Psychosom Med</source> <volume>63</volume>: <fpage>619</fpage>–<lpage>630</lpage>.</citation>
</ref>
<ref id="bibr21-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Delgado</surname><given-names>PL</given-names></name>
<name><surname>Brannan</surname><given-names>SK</given-names></name>
<name><surname>Mallinckrodt</surname><given-names>CH</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Sexual functioning assessed in 4 double-blind placebo- and paroxetine-controlled trials of duloxetine for major depressive disorder</article-title>. <source>J Clin Psychiatry</source> <volume>66</volume>: <fpage>686</fpage>–<lpage>692</lpage>.</citation>
</ref>
<ref id="bibr22-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Demyttenaere</surname><given-names>K</given-names></name>
<name><surname>Huygens</surname><given-names>R</given-names></name>
<name><surname>Van</surname><given-names>BR</given-names></name>
</person-group> (<year>2001</year>) <article-title>Tamsulosin as an effective treatment for reboxetine-associated urinary hesitancy</article-title>. <source>Int Clin Psychopharmacol</source> <volume>16</volume>: <fpage>353</fpage>–<lpage>355</lpage>.</citation>
</ref>
<ref id="bibr23-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Detke</surname><given-names>MJ</given-names></name>
<name><surname>Wiltse</surname><given-names>CG</given-names></name>
<name><surname>Mallinckrodt</surname><given-names>CH</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Duloxetine in the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled trial</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>14</volume>: <fpage>457</fpage>–<lpage>470</lpage>.</citation>
</ref>
<ref id="bibr24-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Deuschle</surname><given-names>M</given-names></name>
</person-group> (<year>2013</year>) <article-title>Effects of antidepressants on glucose metabolism and diabetes mellitus type 2 in adults</article-title>. <source>Curr Opin Psychiatry</source> <volume>26</volume>: <fpage>60</fpage>–<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr25-0269881113492027">
<citation citation-type="web">
<collab>Eli Lilly and Company Limited</collab> (<year>2012</year>) <article-title>Summary of product characteristics</article-title>. <source>Cymbalta 30 mg hard gastro-resistant capsules, Cymbalta 60 mg hard gastro-resistant capsules</source>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/">http://www.medicines.org.uk/</ext-link> (<access-date>accessed 4 June 2013</access-date>). <ext-link ext-link-type="uri" xlink:href="http://emc/medicine/15694/SPC/Cymbalta+30mg+hard+gastro-resistant+capsules%2c+Cymbalta+60mg+hard+gastro-resistant+capsules/">emc/medicine/15694/SPC/Cymbalta+30mg+hard+gastro-resistant+capsules%2c+Cymbalta+60mg+hard+gastro-resistant+capsules/</ext-link> (<access-date>accessed 4 June 2013</access-date>).</citation>
</ref>
<ref id="bibr26-0269881113492027">
<citation citation-type="web">
<collab>Eli Lilly and Company Limited</collab> (<year>2013</year>) <article-title>Summary of product characteristics</article-title>. <source>Strattera 10 mg, 18 mg, 25 mg, 40 mg, 60 mg or 80 mg hard capsules</source>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/">http://www.medicines.org.uk/</ext-link> (<access-date>accessed 4 June 2013</access-date>).</citation>
</ref>
<ref id="bibr27-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Eyding</surname><given-names>D</given-names></name>
<name><surname>Lelgemann</surname><given-names>M</given-names></name>
<name><surname>Grouven</surname><given-names>U</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Reboxetine for acute treatment of major depression: Systematic review and meta-analysis of published and unpublished placebo and selective serotonin reuptake inhibitor controlled trials</article-title>. <source>Brit Med J</source> <volume>341</volume>: <fpage>c4737</fpage>.</citation>
</ref>
<ref id="bibr28-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fava</surname><given-names>M</given-names></name>
<name><surname>McGrath</surname><given-names>PJ</given-names></name>
<name><surname>Sheu</surname><given-names>WP</given-names></name>
</person-group> (<year>2003</year>) <article-title>Switching to reboxetine: An efficacy and safety study in patients with major depressive disorder unresponsive to fluoxetine</article-title>. <source>J Clin Psychopharmacol</source> <volume>23</volume>: <fpage>365</fpage>–<lpage>369</lpage>.</citation>
</ref>
<ref id="bibr29-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Feder</surname><given-names>R</given-names></name>
</person-group> (<year>1995</year>) <article-title>Clonidine treatment of excessive sweating</article-title>. <source>J Clin Psychiatry</source> <volume>56</volume>: <fpage>35</fpage>.</citation>
</ref>
<ref id="bibr30-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ferini-Strambi</surname><given-names>L</given-names></name>
<name><surname>Manconi</surname><given-names>M</given-names></name>
<name><surname>Castronovo</surname><given-names>V</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia</article-title>. <source>J Psychopharmacol</source> <volume>18</volume>: <fpage>417</fpage>–<lpage>422</lpage>.</citation>
</ref>
<ref id="bibr31-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fleishaker</surname><given-names>JC</given-names></name>
<name><surname>Francom</surname><given-names>SF</given-names></name>
<name><surname>Herman</surname><given-names>BD</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Lack of effect of reboxetine on cardiac repolarization</article-title>. <source>Clin Pharmacol Ther</source> <volume>70</volume>: <fpage>261</fpage>–<lpage>269</lpage>.</citation>
</ref>
<ref id="bibr32-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Fowler</surname><given-names>CJ</given-names></name>
<name><surname>Griffiths</surname><given-names>D</given-names></name>
<name><surname>de Groat</surname><given-names>WC</given-names></name>
</person-group> (<year>2008</year>) <article-title>The neural control of micturition</article-title>. <source>Nat Rev Neurosci</source> <volume>9</volume>: <fpage>453</fpage>–<lpage>466</lpage>.</citation>
</ref>
<ref id="bibr33-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Gelenberg</surname><given-names>AJ</given-names></name>
<name><surname>McGahuey</surname><given-names>C</given-names></name>
<name><surname>Laukes</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Mirtazapine substitution in SSRI-induced sexual dysfunction</article-title>. <source>J Clin Psychiatry</source> <volume>61</volume>: <fpage>356</fpage>–<lpage>360</lpage>.</citation>
</ref>
<ref id="bibr34-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ghaleiha</surname><given-names>A</given-names></name>
<name><surname>Shahidi</surname><given-names>KM</given-names></name>
<name><surname>Afzali</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2012</year>) <article-title>Effect of terazosin on sweating in patients with major depressive disorder receiving sertraline: A randomized controlled trial</article-title>. <source>Int J Psychiatry Clin Pract</source> <volume>17</volume>: <fpage>44</fpage>–<lpage>47</lpage>.</citation>
</ref>
<ref id="bibr35-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Giuliano</surname><given-names>F</given-names></name>
<name><surname>Rampin</surname><given-names>O</given-names></name>
</person-group> (<year>2000</year>) <article-title>Central noradrenergic control of penile erection</article-title>. <source>Int J Impot Res</source> <volume>12</volume>: <fpage>S13</fpage>-<lpage>S19</lpage>.</citation>
</ref>
<ref id="bibr36-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hawton</surname><given-names>K</given-names></name>
<name><surname>Bergen</surname><given-names>H</given-names></name>
<name><surname>Simkin</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Toxicity of antidepressants: Rates of suicide relative to prescribing and non-fatal overdose</article-title>. <source>Br J Psychiatry</source> <volume>196</volume>: <fpage>354</fpage>–<lpage>358</lpage>.</citation>
</ref>
<ref id="bibr37-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Henry</surname><given-names>JA</given-names></name>
<name><surname>Alexander</surname><given-names>CA</given-names></name>
<name><surname>Sener</surname><given-names>EK</given-names></name>
</person-group> (<year>1995</year>) <article-title>Relative mortality from overdose of antidepressants</article-title>. <source>Brit Med J</source> <volume>310</volume>: <fpage>221</fpage>–<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr38-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jacob</surname><given-names>J</given-names></name>
<name><surname>Albert</surname><given-names>D</given-names></name>
<name><surname>Heard</surname><given-names>K</given-names></name>
</person-group> (<year>2012</year>) <article-title>Single-agent duloxetine ingestions</article-title>. <source>Hum Exp Toxicol</source> <volume>32</volume>: <fpage>427</fpage>–<lpage>433</lpage>.</citation>
</ref>
<ref id="bibr39-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Jefferson</surname><given-names>JW</given-names></name>
</person-group> (<year>1975</year>) <article-title>A review of the cardiovascular effects and toxicity of tricyclic antidepressants</article-title>. <source>Psychosom Med</source> <volume>37</volume>: <fpage>160</fpage>–<lpage>179</lpage>.</citation>
</ref>
<ref id="bibr40-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kasper</surname><given-names>S</given-names></name>
<name><surname>Wolf</surname><given-names>R</given-names></name>
</person-group> (<year>2002</year>) <article-title>Successful treatment of reboxetine-induced urinary hesitancy with tamsulosin</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>12</volume>: <fpage>119</fpage>–<lpage>122</lpage>.</citation>
</ref>
<ref id="bibr41-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Katona</surname><given-names>C</given-names></name>
<name><surname>Bercoff</surname><given-names>E</given-names></name>
<name><surname>Chiu</surname><given-names>E</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Reboxetine versus imipramine in the treatment of elderly patients with depressive disorders: A double-blind randomised trial</article-title>. <source>J Affect Disord</source> <volume>55</volume>: <fpage>203</fpage>–<lpage>213</lpage>.</citation>
</ref>
<ref id="bibr42-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>Rizvi</surname><given-names>S</given-names></name>
</person-group> (<year>2009</year>) <article-title>Sexual dysfunction, depression, and the impact of antidepressants. J</article-title> <source>Clin Psychopharmacol</source> <volume>29</volume>: <fpage>157</fpage>–<lpage>164</lpage>.</citation>
</ref>
<ref id="bibr43-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
<name><surname>Dickens</surname><given-names>SE</given-names></name>
<name><surname>Eisfeld</surname><given-names>BS</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Sexual dysfunction before antidepressant therapy in major depression</article-title>. <source>J Affect Disord</source> <volume>56</volume>: <fpage>201</fpage>–<lpage>208</lpage>.</citation>
</ref>
<ref id="bibr44-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Khawaja</surname><given-names>IS</given-names></name>
<name><surname>Feinstein</surname><given-names>RE</given-names></name>
</person-group> (<year>2003</year>) <article-title>Cardiovascular effects of selective serotonin reuptake inhibitors and other novel antidepressants</article-title>. <source>Heart Dis</source> <volume>5</volume>: <fpage>153</fpage>–<lpage>160</lpage>.</citation>
</ref>
<ref id="bibr45-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kuenzel</surname><given-names>HE</given-names></name>
<name><surname>Murck</surname><given-names>H</given-names></name>
<name><surname>Held</surname><given-names>K</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Reboxetine induces similar sleep-EEG changes like SSRI’s in patients with depression</article-title>. <source>Pharmacopsychiatry</source> <volume>37</volume>: <fpage>193</fpage>–<lpage>195</lpage>.</citation>
</ref>
<ref id="bibr46-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Langworth</surname><given-names>S</given-names></name>
<name><surname>Bodlund</surname><given-names>O</given-names></name>
<name><surname>Agren</surname><given-names>H</given-names></name>
</person-group> (<year>2006</year>) <article-title>Efficacy and tolerability of reboxetine compared with citalopram: A double-blind study in patients with major depressive disorder</article-title>. <source>J Clin Psychopharmacol</source> <volume>26</volume>: <fpage>121</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr47-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mbaya</surname><given-names>P</given-names></name>
<name><surname>Alam</surname><given-names>F</given-names></name>
<name><surname>Ashim</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder</article-title>. <source>Hum Psychopharmacol</source> <volume>22</volume>: <fpage>129</fpage>–<lpage>133</lpage>.</citation>
</ref>
<ref id="bibr48-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McIntyre</surname><given-names>RS</given-names></name>
<name><surname>Panjwani</surname><given-names>ZD</given-names></name>
<name><surname>Nguyen</surname><given-names>HT</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>The hepatic safety profile of duloxetine: A review</article-title>. <source>Expert Opin Drug Metab Toxicol</source> <volume>4</volume>: <fpage>281</fpage>–<lpage>285</lpage>.</citation>
</ref>
<ref id="bibr49-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>McIntyre</surname><given-names>RS</given-names></name>
<name><surname>Soczynska</surname><given-names>JK</given-names></name>
<name><surname>Konarski</surname><given-names>JZ</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>The effect of antidepressants on glucose homeostasis and insulin sensitivity: Synthesis and mechanisms</article-title>. <source>Expert Opin Drug Saf</source> <volume>5</volume>: <fpage>157</fpage>–<lpage>168</lpage>.</citation>
</ref>
<ref id="bibr50-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Marcy</surname><given-names>TR</given-names></name>
<name><surname>Britton</surname><given-names>ML</given-names></name>
</person-group> (<year>2005</year>) <article-title>Antidepressant-induced sweating</article-title>. <source>Ann Pharmacother</source> <volume>39</volume>: <fpage>748</fpage>–<lpage>752</lpage>.</citation>
</ref>
<ref id="bibr51-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Martinez</surname><given-names>C</given-names></name>
<name><surname>Assimes</surname><given-names>TL</given-names></name>
<name><surname>Mines</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Use of venlafaxine compared with other antidepressants and the risk of sudden cardiac death or near death: A nested case-control study</article-title>. <source>Brit Med J</source> <volume>340</volume>: <fpage>c249</fpage>.</citation>
</ref>
<ref id="bibr52-0269881113492027">
<citation citation-type="gov">
<collab>Medicines and Healthcare Products Regulatory Agency</collab> (<year>2011</year>) <source>MHRA UK Public Assessment Report: Reboxetine: A review of the benefits and risks</source>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con129107.pdf">http://www.mhra.gov.uk/home/groups/pl-p/documents/websiteresources/con129107.pdf</ext-link> (<access-date>accessed 4 June 2013</access-date>).</citation>
</ref>
<ref id="bibr53-0269881113492027">
<citation citation-type="gov">
<collab>Medicines and Health Care Regulatory Authority</collab> (<year>2006</year>). <article-title>Message from Professor G Duff, Chairman, Commission on Human Medicines - Strattera (atomoxetine) – conclusions of risk: benefit review</article-title>. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.mhra.gov.uk/home/groups/comms-po/documents/websiteresources/con2023220.pdf">http://www.mhra.gov.uk/home/groups/comms-po/documents/websiteresources/con2023220.pdf</ext-link> (<access-date>accessed 4 June 2013</access-date>).</citation>
</ref>
<ref id="bibr54-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Mehtonen</surname><given-names>OP</given-names></name>
<name><surname>Sogaard</surname><given-names>J</given-names></name>
<name><surname>Roponen</surname><given-names>P</given-names></name><etal/>
</person-group>. (<year>2000</year>) <article-title>Randomized, double-blind comparison of venlafaxine and sertraline in outpatients with major depressive disorder. Venlafaxine 631 Study Group</article-title>. <source>J Clin Psychiatry</source> <volume>61</volume>: <fpage>95</fpage>–<lpage>100</lpage>.</citation>
</ref>
<ref id="bibr55-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Michelson</surname><given-names>D</given-names></name>
<name><surname>Adler</surname><given-names>L</given-names></name>
<name><surname>Spencer</surname><given-names>T</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies</article-title>. <source>Biol Psychiatry</source> <volume>53</volume>: <fpage>112</fpage>–<lpage>120</lpage>.</citation>
</ref>
<ref id="bibr56-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montejo</surname><given-names>AL</given-names></name>
<name><surname>Llorca</surname><given-names>G</given-names></name>
<name><surname>Izquierdo</surname><given-names>JA</given-names></name><etal/>
</person-group>. (<year>2001</year>) <article-title>Incidence of sexual dysfunction associated with antidepressant agents: A prospective multicenter study of 1022 outpatients. Spanish Working Group for the Study of Psychotropic-Related Sexual Dysfunction</article-title>. <source>J Clin Psychiatry</source> <volume>62</volume>: <fpage>10</fpage>–<lpage>21</lpage>.</citation>
</ref>
<ref id="bibr57-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Montgomery</surname><given-names>SA</given-names></name>
<name><surname>Huusom</surname><given-names>AK</given-names></name>
<name><surname>Bothmer</surname><given-names>J.</given-names></name>
</person-group> (<year>2004</year>) <article-title>A randomised study comparing escitalopram with venlafaxine XR in primary care patients with major depressive disorder</article-title>. <source>Neuropsychobiology</source> <volume>50</volume>: <fpage>57</fpage>–<lpage>64</lpage>.</citation>
</ref>
<ref id="bibr58-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Movig</surname><given-names>KL</given-names></name>
<name><surname>Leufkens</surname><given-names>HG</given-names></name>
<name><surname>Lenderink</surname><given-names>AW</given-names></name><etal/>
</person-group>. (<year>2002</year>) <article-title>Serotonergic antidepressants associated with an increased risk for hyponatraemia in the elderly</article-title>. <source>Eur J Clin Pharmacol</source> <volume>58</volume>: <fpage>143</fpage>–<lpage>148</lpage>.</citation>
</ref>
<ref id="bibr59-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Munoz</surname><given-names>M</given-names></name>
<name><surname>Bancroft</surname><given-names>J</given-names></name>
<name><surname>Beard</surname><given-names>M</given-names></name>
</person-group> (<year>1994</year>) <article-title>Evaluating the effects of an alpha-2 adrenoceptor antagonist on erectile function in the human male. 2. The erectile response to erotic stimuli in men with erectile dysfunction, in relation to age and in comparison with normal volunteers</article-title>. <source>Psychopharmacology (Berl)</source> <volume>115</volume>: <fpage>471</fpage>–<lpage>477</lpage>.</citation>
</ref>
<ref id="bibr60-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Musselman</surname><given-names>DL</given-names></name>
<name><surname>Evans</surname><given-names>DL</given-names></name>
<name><surname>Nemeroff</surname><given-names>CB</given-names></name>
</person-group> (<year>1998</year>) <article-title>The relationship of depression to cardiovascular disease: Epidemiology, biology, and treatment</article-title>. <source>Arch Gen Psychiatry</source> <volume>55</volume>: <fpage>580</fpage>–<lpage>592</lpage>.</citation>
</ref>
<ref id="bibr61-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>2002</year>) <article-title>Tolerability and safety aspects of mirtazapine</article-title>. <source>Hum Psychopharmacol</source> <volume>17</volume>: <fpage>S37</fpage>-<lpage>S41</lpage>.</citation>
</ref>
<ref id="bibr62-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Nutt</surname><given-names>DJ</given-names></name>
</person-group> (<year>2006</year>) <article-title>The role of dopamine and norepinephrine in depression and antidepressant treatment</article-title>. <source>J Clin Psychiatry</source> <volume>67</volume>: <fpage>S3</fpage>–<lpage>S8</lpage>.</citation>
</ref>
<ref id="bibr63-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ozmenler</surname><given-names>NK</given-names></name>
<name><surname>Karlidere</surname><given-names>T</given-names></name>
<name><surname>Bozkurt</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Mirtazapine augmentation in depressed patients with sexual dysfunction due to selective serotonin reuptake inhibitors</article-title>. <source>Hum Psychopharmacol</source> <volume>23</volume>: <fpage>321</fpage>–<lpage>326</lpage>.</citation>
</ref>
<ref id="bibr64-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Papakostas</surname><given-names>GI</given-names></name>
<name><surname>Nelson</surname><given-names>JC</given-names></name>
<name><surname>Kasper</surname><given-names>S</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>A meta-analysis of clinical trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin reuptake inhibitors for the treatment of major depressive disorder</article-title>. <source>Eur Neuropsychopharmacol</source> <volume>18</volume>: <fpage>122</fpage>–<lpage>127</lpage>.</citation>
</ref>
<ref id="bibr65-0269881113492027">
<citation citation-type="confproc">
<person-group person-group-type="author">
<name><surname>Parmar</surname><given-names>S</given-names></name>
<name><surname>Behere</surname><given-names>PB</given-names></name>
</person-group> (<year>2010</year>) <article-title>Hyponatraemia in patients receiving selective serontonin re-uptake inhibitors (SSRIs) and tricyclic antidepressants (TCAs): A controlled study</article-title>. <conf-name>Conference abstract, 62nd Annual Conference of Indian Psychiatric Society</conf-name>, <conf-date>17–20 January 2010</conf-date>, <conf-loc>Jaipur, India</conf-loc>.</citation>
</ref>
<ref id="bibr66-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Peretti</surname><given-names>S</given-names></name>
<name><surname>Judge</surname><given-names>R</given-names></name>
<name><surname>Hindmarch</surname><given-names>I</given-names></name>
</person-group> (<year>2000</year>) <article-title>Safety and tolerability considerations: Tricyclic antidepressants vs. selective serotonin reuptake inhibitors</article-title>. <source>Acta Psychiatr Scand Suppl</source> <volume>403</volume>: <fpage>17</fpage>–<lpage>25</lpage>.</citation>
</ref>
<ref id="bibr67-0269881113492027">
<citation citation-type="web">
<collab>Pfizer Limited</collab> (<year>2012</year>) <article-title>Summary of product characteristics</article-title>. Efexor XL. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.medicines.org.uk/emc/medicine/2210/SPC/Efexor+XL/">http://www.medicines.org.uk/emc/medicine/2210/SPC/Efexor+XL/</ext-link></citation>
</ref>
<ref id="bibr68-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Pinder</surname><given-names>RM</given-names></name>
<name><surname>Brogden</surname><given-names>RN</given-names></name>
<name><surname>Speight</surname><given-names>TM</given-names></name><etal/>
</person-group>. (<year>1977</year>) <article-title>Viloxazine: A review of its pharmacological properties and therapeutic efficacy in depressive illness</article-title>. <source>Drugs</source> <volume>13</volume>: <fpage>401</fpage>–<lpage>421</lpage>.</citation>
</ref>
<ref id="bibr69-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Preskorn</surname><given-names>SH</given-names></name>
</person-group> (<year>2004</year>) <article-title>Reboxetine: A norepinephrine selective reuptake pump inhibitor</article-title>. <source>J Psychiatr Pract</source> <volume>10</volume>: <fpage>57</fpage>–<lpage>63</lpage>.</citation>
</ref>
<ref id="bibr70-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Quirk</surname><given-names>KC</given-names></name>
<name><surname>Einarson</surname><given-names>TR</given-names></name>
</person-group> (<year>1982</year>) <article-title>Sexual dysfunction and clomipramine</article-title>. <source>Can J Psychiatry</source> <volume>27</volume>: <fpage>228</fpage>–<lpage>231</lpage>.</citation>
</ref>
<ref id="bibr71-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ranieri</surname><given-names>P</given-names></name>
<name><surname>Franzoni</surname><given-names>S</given-names></name>
<name><surname>Trabucchi</surname><given-names>M</given-names></name>
</person-group> (<year>2000</year>) <article-title>Reboxetine and hyponatremia</article-title>. <source>N Engl J Med</source> <volume>342</volume>: <fpage>215</fpage>–<lpage>216</lpage>.</citation>
</ref>
<ref id="bibr72-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Raskin</surname><given-names>J</given-names></name>
<name><surname>Goldstein</surname><given-names>DJ</given-names></name>
<name><surname>Mallinckrodt</surname><given-names>CH</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Duloxetine in the long-term treatment of major depressive disorder</article-title>. <source>J Clin Psychiatry</source> <volume>64</volume>: <fpage>1237</fpage>–<lpage>1244</lpage>.</citation>
</ref>
<ref id="bibr73-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Ravindran</surname><given-names>LN</given-names></name>
<name><surname>Eisfeld</surname><given-names>BS</given-names></name>
<name><surname>Kennedy</surname><given-names>SH</given-names></name>
</person-group> (<year>2008</year>) <article-title>Combining mirtazapine and duloxetine in treatment-resistant depression improves outcomes and sexual function</article-title>. <source>J Clin Psychopharmacol</source> <volume>28</volume>: <fpage>107</fpage>–<lpage>108</lpage>.</citation>
</ref>
<ref id="bibr74-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Richelson</surname><given-names>E</given-names></name>
</person-group> (<year>1979</year>) <article-title>Tricyclic antidepressants and histamine H1 receptors</article-title>. <source>Mayo Clin Proc</source> <volume>54</volume>: <fpage>669</fpage>–<lpage>674</lpage>.</citation>
</ref>
<ref id="bibr75-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Roos</surname><given-names>JC</given-names></name>
</person-group> (<year>1983</year>) <article-title>Cardiac effects of antidepressant drugs. A comparison of the tricyclic antidepressants and fluvoxamine</article-title>. <source>Br J Clin Pharmacol</source> <volume>15</volume>: <fpage>S439</fpage>-<lpage>S445</lpage>.</citation>
</ref>
<ref id="bibr76-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rudolph</surname><given-names>RL</given-names></name>
<name><surname>Derivan</surname><given-names>AT</given-names></name>
</person-group> (<year>1996</year>) <article-title>The safety and tolerability of venlafaxine hydrochloride: Analysis of the clinical trials database</article-title>. <source>J Clin Psychopharmacol</source> <volume>16</volume>: <fpage>S54</fpage>-<lpage>S59</lpage>.</citation>
</ref>
<ref id="bibr77-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rutledge</surname><given-names>T</given-names></name>
<name><surname>Reis</surname><given-names>VA</given-names></name>
<name><surname>Linke</surname><given-names>SE</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Depression in heart failure: A meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes</article-title>. <source>J Am Coll Cardiol</source> <volume>48</volume>: <fpage>1527</fpage>–<lpage>1537</lpage>.</citation>
</ref>
<ref id="bibr78-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sawant</surname><given-names>S</given-names></name>
<name><surname>Daviss</surname><given-names>SR</given-names></name>
</person-group> (<year>2004</year>) <article-title>Seizures and prolonged QTc with atomoxetine overdose</article-title>. <source>Am J Psychiatry</source> <volume>161</volume>: <fpage>757</fpage>.</citation>
</ref>
<ref id="bibr79-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Schatzberg</surname><given-names>AF</given-names></name>
</person-group> (<year>2000</year>) <article-title>Clinical efficacy of reboxetine in major depression</article-title>. <source>J Clin Psychiatry</source> <volume>61</volume>: <fpage>S31</fpage>–<lpage>S38</lpage>.</citation>
</ref>
<ref id="bibr80-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Serretti</surname><given-names>A</given-names></name>
<name><surname>Chiesa</surname><given-names>A</given-names></name>
</person-group> (<year>2009</year>) <article-title>Treatment-emergent sexual dysfunction related to antidepressants: A meta-analysis</article-title>. <source>J Clin Psychopharmacol</source> <volume>29</volume>: <fpage>259</fpage>–<lpage>266</lpage>.</citation>
</ref>
<ref id="bibr81-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Simpson</surname><given-names>D</given-names></name>
<name><surname>Plosker</surname><given-names>GL</given-names></name>
</person-group> (<year>2004</year>) <article-title>Atomoxetine: A review of its use in adults with attention deficit hyperactivity disorder</article-title>. <source>Drugs</source> <volume>64</volume>: <fpage>205</fpage>–<lpage>222</lpage>.</citation>
</ref>
<ref id="bibr82-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>T</given-names></name>
</person-group> (<year>2007</year>) <article-title>Atomoxetine-induced hyponatremia</article-title>. <source>Aust N Z J Psychiatry</source> <volume>41</volume>: <fpage>458</fpage>.</citation>
</ref>
<ref id="bibr83-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Southwick</surname><given-names>SM</given-names></name>
<name><surname>Bremner</surname><given-names>JD</given-names></name>
<name><surname>Rasmusson</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>1999</year>) <article-title>Role of norepinephrine in the pathophysiology and treatment of posttraumatic stress disorder</article-title>. <source>Biol Psychiatry</source> <volume>46</volume>: <fpage>1192</fpage>–<lpage>1204</lpage>.</citation>
</ref>
<ref id="bibr84-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
</person-group> (<year>1998</year>) <article-title>Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects</article-title>. <source>J Clin Psychiatry</source> <volume>59</volume>: <fpage>S23</fpage>–<lpage>S29</lpage>.</citation>
</ref>
<ref id="bibr85-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
<name><surname>Grady</surname><given-names>MM</given-names></name>
<name><surname>Moret</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>SNRIs: Their pharmacology, clinical efficacy, and tolerability in comparison with other classes of antidepressants</article-title>. <source>CNS Spectr</source> <volume>10</volume>: <fpage>732</fpage>–<lpage>747</lpage>.</citation>
</ref>
<ref id="bibr86-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Stahl</surname><given-names>SM</given-names></name>
<name><surname>Mendels</surname><given-names>J</given-names></name>
<name><surname>Schwartz</surname><given-names>GE</given-names></name>
</person-group> (<year>2002</year>) <article-title>Effects of reboxetine on anxiety, agitation, and insomnia: Results of a pooled evaluation of randomized clinical trials</article-title>. <source>J Clin Psychopharmacol</source> <volume>22</volume>: <fpage>388</fpage>–<lpage>392</lpage>.</citation>
</ref>
<ref id="bibr87-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Strombom</surname><given-names>I</given-names></name>
<name><surname>Wernicke</surname><given-names>JF</given-names></name>
<name><surname>Seeger</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2008</year>) <article-title>Hepatic effects of duloxetine-III: Analysis of hepatic events using external data sources</article-title>. <source>Curr Drug Saf</source> <volume>3</volume>: <fpage>154</fpage>–<lpage>162</lpage>.</citation>
</ref>
<ref id="bibr88-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sumner</surname><given-names>CR</given-names></name>
<name><surname>Schuh</surname><given-names>KJ</given-names></name>
<name><surname>Sutton</surname><given-names>VK</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Placebo-controlled study of the effects of atomoxetine on bladder control in children with nocturnal enuresis</article-title>. <source>J Child Adolesc Psychopharmacol</source> <volume>16</volume>: <fpage>699</fpage>–<lpage>711</lpage>.</citation>
</ref>
<ref id="bibr89-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szabadi</surname><given-names>E</given-names></name>
</person-group> (<year>1998</year>) <article-title>Doxazosin for reboxetine-induced urinary hesitancy</article-title>. <source>Br J Psychiatry</source> <volume>173</volume>: <fpage>441</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr90-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Szabadi</surname><given-names>E</given-names></name>
<name><surname>Bradshaw</surname><given-names>CM</given-names></name>
<name><surname>Boston</surname><given-names>PF</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>The human pharmacology of reboxetine</article-title>. <source>Hum Psychopharmacol</source> <volume>13</volume>: <fpage>S3</fpage>-<lpage>S12</lpage>.</citation>
</ref>
<ref id="bibr91-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tanum</surname><given-names>L</given-names></name>
</person-group> (<year>2000</year>) <article-title>Reboxetine: Tolerability and safety profile in patients with major depression</article-title>. <source>Acta Psychiatr Scand Suppl</source> <volume>402</volume>: <fpage>37</fpage>–<lpage>40</lpage>.</citation>
</ref>
<ref id="bibr92-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Tatsumi</surname><given-names>M</given-names></name>
<name><surname>Groshan</surname><given-names>K</given-names></name>
<name><surname>Blakely</surname><given-names>RD</given-names></name><etal/>
</person-group>. (<year>1997</year>) <article-title>Pharmacological profile of antidepressants and related compounds at human monoamine transporters</article-title>. <source>Eur J Pharmacol</source> <volume>340</volume>: <fpage>249</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr93-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>D</given-names></name>
</person-group> (<year>2008</year>) <article-title>Antidepressant drugs and cardiovascular pathology: A clinical overview of effectiveness and safety</article-title>. <source>Acta Psychiatr Scand</source> <volume>118</volume>: <fpage>434</fpage>–<lpage>442</lpage>.</citation>
</ref>
<ref id="bibr94-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>D</given-names></name>
<name><surname>Scott</surname><given-names>JR</given-names></name>
</person-group> (<year>2006</year>) <article-title>Volte-face on venlafaxine-reasons and reflections</article-title>. <source>J Psychopharmacol</source> <volume>20</volume>: <fpage>597</fpage>–<lpage>601</lpage>.</citation>
</ref>
<ref id="bibr95-0269881113492027">
<citation citation-type="book">
<person-group person-group-type="author">
<name><surname>Taylor</surname><given-names>D</given-names></name>
<name><surname>Paton</surname><given-names>C</given-names></name>
<name><surname>Kapur</surname><given-names>S</given-names></name>
</person-group> (<year>2012</year>) <source>Maudsley Prescribing Guidelines in Psychiatry</source>. <edition>11th ed.</edition> <publisher-loc>Oxford, UK</publisher-loc>: <publisher-name>Wiley-Blackwell</publisher-name>.</citation>
</ref>
<ref id="bibr96-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thanacoody</surname><given-names>HK</given-names></name>
<name><surname>Thomas</surname><given-names>SH</given-names></name>
</person-group> (<year>2005</year>) <article-title>Tricyclic antidepressant poisoning: Cardiovascular toxicity</article-title>. <source>Toxicol Rev</source> <volume>24</volume>: <fpage>205</fpage>–<lpage>214</lpage>.</citation>
</ref>
<ref id="bibr97-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thase</surname><given-names>ME</given-names></name>
</person-group> (<year>1998</year>) <article-title>Effects of venlafaxine on blood pressure: A meta-analysis of original data from 3744 depressed patients</article-title>. <source>J Clin Psychiatry</source> <volume>59</volume>: <fpage>502</fpage>–<lpage>508</lpage>.</citation>
</ref>
<ref id="bibr98-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thase</surname><given-names>ME</given-names></name>
<name><surname>Shelton</surname><given-names>RC</given-names></name>
<name><surname>Khan</surname><given-names>A</given-names></name>
</person-group> (<year>2006</year>) <article-title>Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: A randomized comparison of standard- and higher-dosing strategies</article-title>. <source>J Clin Psychopharmacol</source> <volume>26</volume>: <fpage>250</fpage>–<lpage>258</lpage>.</citation>
</ref>
<ref id="bibr99-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thase</surname><given-names>ME</given-names></name>
<name><surname>Tran</surname><given-names>PV</given-names></name>
<name><surname>Wiltse</surname><given-names>C</given-names></name><etal/>
</person-group>. (<year>2005</year>) <article-title>Cardiovascular profile of duloxetine, a dual reuptake inhibitor of serotonin and norepinephrine</article-title>. <source>J Clin Psychopharmacol</source> <volume>25</volume>: <fpage>132</fpage>–<lpage>140</lpage>.</citation>
</ref>
<ref id="bibr100-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thombs</surname><given-names>BD</given-names></name>
<name><surname>Bass</surname><given-names>EB</given-names></name>
<name><surname>Ford</surname><given-names>DE</given-names></name><etal/>
</person-group>. (<year>2006</year>) <article-title>Prevalence of depression in survivors of acute myocardial infarction</article-title>. <source>J Gen Intern Med</source> <volume>21</volume>: <fpage>30</fpage>–<lpage>38</lpage>.</citation>
</ref>
<ref id="bibr101-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Thor</surname><given-names>KB</given-names></name>
<name><surname>Kirby</surname><given-names>M</given-names></name>
<name><surname>Viktrup</surname><given-names>L</given-names></name>
</person-group> (<year>2007</year>) <article-title>Serotonin and noradrenaline involvement in urinary incontinence, depression and pain: Scientific basis for overlapping clinical efficacy from a single drug, duloxetine</article-title>. <source>Int J Clin Pract</source> <volume>61</volume>: <fpage>1349</fpage>–<lpage>1355</lpage>.</citation>
</ref>
<ref id="bibr102-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Trindade</surname><given-names>E</given-names></name>
<name><surname>Menon</surname><given-names>D</given-names></name>
<name><surname>Topfer</surname><given-names>LA</given-names></name><etal/>
</person-group>. (<year>1998</year>) <article-title>Adverse effects associated with selective serotonin reuptake inhibitors and tricyclic antidepressants: A meta-analysis</article-title>. <source>CMAJ</source> <volume>159</volume>: <fpage>1245</fpage>–<lpage>1252</lpage>.</citation>
</ref>
<ref id="bibr103-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Versiani</surname><given-names>M</given-names></name>
<name><surname>Amin</surname><given-names>M</given-names></name>
<name><surname>Chouinard</surname><given-names>G</given-names></name>
</person-group> (<year>2000</year>) <article-title>Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder</article-title>. <source>J Clin Psychopharmacol</source> <volume>20</volume>: <fpage>28</fpage>–<lpage>34</lpage>.</citation>
</ref>
<ref id="bibr104-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vey</surname><given-names>EL</given-names></name>
<name><surname>Kovelman</surname><given-names>I</given-names></name>
</person-group> (<year>2010</year>) <article-title>Adverse events, toxicity and post-mortem data on duloxetine: Case reports and literature survey</article-title>. <source>J Forensic Leg Med</source> <volume>17</volume>: <fpage>175</fpage>–<lpage>185</lpage>.</citation>
</ref>
<ref id="bibr105-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Viktrup</surname><given-names>L</given-names></name>
<name><surname>Pangallo</surname><given-names>BA</given-names></name>
<name><surname>Detke</surname><given-names>MJ</given-names></name><etal/>
</person-group>. (<year>2004</year>) <article-title>Urinary side effects of duloxetine in the treatment of depression and stress urinary incontinence</article-title>. <source>Prim Care Companion J Clin Psychiatry</source> <volume>6</volume>: <fpage>65</fpage>–<lpage>73</lpage>.</citation>
</ref>
<ref id="bibr106-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vuppalanchi</surname><given-names>R</given-names></name>
<name><surname>Hayashi</surname><given-names>PH</given-names></name>
<name><surname>Chalasani</surname><given-names>N</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Duloxetine hepatotoxicity: A case-series from the drug-induced liver injury network</article-title>. <source>Aliment Pharmacol Ther</source> <volume>32</volume>: <fpage>1174</fpage>–<lpage>1183</lpage>.</citation>
</ref>
<ref id="bibr107-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wade</surname><given-names>A</given-names></name>
<name><surname>Gembert</surname><given-names>K</given-names></name>
<name><surname>Florea</surname><given-names>I</given-names></name>
</person-group> (<year>2007</year>) <article-title>A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder</article-title>. <source>Curr Med Res Opin</source> <volume>23</volume>: <fpage>1605</fpage>–<lpage>1614</lpage>.</citation>
</ref>
<ref id="bibr108-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Watanabe</surname><given-names>N</given-names></name>
<name><surname>Omori</surname><given-names>IM</given-names></name>
<name><surname>Nakagawa</surname><given-names>A</given-names></name><etal/>
</person-group>. (<year>2010</year>) <article-title>Safety reporting and adverse-event profile of mirtazapine described in randomized controlled trials in comparison with other classes of antidepressants in the acute-phase treatment of adults with depression: Systematic review and meta-analysis</article-title>. <source>CNS Drugs</source> <volume>24</volume>: <fpage>35</fpage>–<lpage>53</lpage>.</citation>
</ref>
<ref id="bibr109-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Werneke</surname><given-names>U</given-names></name>
<name><surname>Northey</surname><given-names>S</given-names></name>
<name><surname>Bhugra</surname><given-names>D</given-names></name>
</person-group> (<year>2006</year>) <article-title>Antidepressants and sexual dysfunction</article-title>. <source>Acta Psychiatr Scand</source> <volume>114</volume>: <fpage>384</fpage>–<lpage>397</lpage>.</citation>
</ref>
<ref id="bibr110-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wernicke</surname><given-names>J</given-names></name>
<name><surname>Lledo</surname><given-names>A</given-names></name>
<name><surname>Raskin</surname><given-names>J</given-names></name><etal/>
</person-group>. (<year>2007</year>) <article-title>An evaluation of the cardiovascular safety profile of duloxetine: Findings from 42 placebo-controlled studies</article-title>. <source>Drug Saf</source> <volume>30</volume>: <fpage>437</fpage>–<lpage>455</lpage>.</citation>
</ref>
<ref id="bibr111-0269881113492027">
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wernicke</surname><given-names>JF</given-names></name>
<name><surname>Faries</surname><given-names>D</given-names></name>
<name><surname>Girod</surname><given-names>D</given-names></name><etal/>
</person-group>. (<year>2003</year>) <article-title>Cardiovascular effects of atomoxetine in children, adolescents, and adults</article-title>. <source>Drug Saf</source> <volume>26</volume>: <fpage>729</fpage>–<lpage>740</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>